Aurobindo Pharma has reported results for third quarter ended December 31, 2012.
The company has posted 11-fold rise in its net profit of Rs 144.28 crore for the quarter as compared to Rs 12.93 crore for the same quarter in the previous year. Total income from operation of the company has increased by 19.01% at Rs 1432.45 crore for quarter under review as compared to Rs 1203.61 crore for the quarter ended December 31, 2011.
On consolidated basis, the company has reported a net profit of Rs 91.81 crore for the quarter as compared to a net loss of Rs 28.54 crore for the same quarter in the previous year. Total income of the company has increased by 22.17% at Rs 1575.73 crore for quarter under review as compared to Rs 1289.74 crore for the quarter ended December 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.20 |
| Dr. Reddys Lab | 1322.95 |
| Cipla | 1309.90 |
| Zydus Lifesciences | 891.65 |
| Lupin | 2303.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: